
About Innova Captab Limited
Data last updated:
Innova Captab Limited is a public limited company based in Thane, Maharashtra, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 03 January 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24246MH2005PLC150371. Its GSTIN is 27AABCH5082R1ZZ (Maharashtra). The company holds 8 GST registrations, of which 6 are active. It is a listed company.
The company has an authorised share capital of ₹66 Cr and a paid-up capital of ₹57.22 Cr. It was formerly known as Innova Captab Private Limited and Harun Health Care Private Limited. It is led by directors including Vinay Kumar Lohariwala (Managing Director) and Jayant Vasudeo Rao (Whole-Time Director).
Its last annual general meeting (AGM) was held on 31 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Thane, Maharashtra.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,630.02 Cr, a growth of 31.06% compared to the previous year. The net worth stands at ₹1,090.8 Cr (up 13.69% YoY). Total assets are valued at ₹1,446.4 Cr (up 10.63% YoY).
The company has about 1,246 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Innova Captab. As per MCA filings, the company has open charges of ₹505.32 Cr and satisfied charges of ₹158.4 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website innovacaptab.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address1513 15th Floor Satra Plaza Chs Ltd., Plot No. 19 & 20 Sector – 19D Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Name History of Innova Captab
Innova Captab has undergone 2 name changes throughout its history. The company was previously known as Innova Captab Private Limited, and Harun Health Care Private Limited. The current legal name is Innova Captab Limited.
| Company Name | Status |
|---|---|
| Innova Captab Limited | Current |
| Innova Captab Private Limited | Previous |
| Harun Health Care Private Limited | Previous |
CIN History of Innova Captab
Innova Captab has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24246MH2005PLC150371, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24246MH2005PLC150371 | Current |
| U24246MH2005PTC150371 | Previous |
| U24246MH2005PLC150371 | Previous |
Associated Brands with Innova Captab
Innova Captab operates one associated brand: Innova Captab. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations are manufactured by Innova Captab as a CDMO. | innovacaptab.com |
Competitors & Alternatives of Innova Captab
Brands and companies operating in the same space as Innova Captab Limited include Pharmaron, Pfizer, Lonza and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
| | Drug discovery and development services for small molecules are provided. | Beijing, China, China | 2003 |
| | Pharmaceutical products for treating multiple diseases are provided. | New York, United States, United States | 1849 |
| | CDMO services for pharma, biotech, and specialty ingredients are provided. | Basel, Switzerland, Switzerland | 1897 |
| | AI powered scientific data management and workflow automation solutions | - | 2005 |
| | Generic drugs and clinical research services are provided globally. | - | 1885 |
| | Laboratory testing, clinical trial research, and biopharma services are provided. | Johnson City, United States, United States | 2002 |
| | Developer of therapeutics for oncology and dermatology | Panchkula, India, India | 2005 |
| | Novel point-of-care testing and low-dose interferon therapeutics are developed. | San Diego, United States, United States | 1986 |
| | Provider of synthetic biology and AI-based technology for generative protein design | Vilnius, Lithuania, Lithuania | 2018 |
Business Activity of Innova Captab
The main business activity of Innova Captab is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Innova Captab Limited
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Innova Captab
Innova Captab Limited is audited by B S R AND Co. LLP for the financial year 2025.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| B S R AND Co. LLP | Locked | Locked | Locked |
Complete auditor history for Innova Captab Limited
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Innova Captab Limited
Innova Captab has 8 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jayant Vasudeo Rao Also directs: Sharon Bio-Medicine Limited | Whole-Time Director | 22 Nov 2017 | 8 Years 10 Months | Current |
| Shirish Gundopant Belapure Also directs: Bellapure Onco Phytoceuticals LLP, Jubilant Pharmova Limited, Corona Remedies Limited and 3 more | Director | 01 Apr 2022 | 4 Years 6 Months | Current |
| Sudhir Kumar Bassi Also directs: Saatvik Green Energy Limited | Director | 01 Apr 2022 | 4 Years 6 Months | Current |
| Priyanka Dixit Also directs: Zuron Fin-Tech Private Limited, Jivfin Ventures Private Limited | Director | 01 Apr 2022 | 4 Years 6 Months | Current |
| Archit Aggarwal Also directs: Innoventis Medicare Limited, Archit Infrastructure and Developers LLP, Vga Enterprises LLP and 5 more | Director | 01 Apr 2022 | 4 Years 6 Months | Current |
| Manoj Kumar Lohariwala | Whole-Time Director | 03 Jun 2009 | 17 Years 4 Months | Current |
Financials of Innova Captab Limited FY 2025-26 filings available
Innova Captab Limited reported revenue of ₹1,630.02 Cr (up 31.06% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,630 | 1,244 | 1,081 | 926 | 801 | 411 | 373 |
| Revenue growth | +31.2% | +14.1% | +14.0% | +15.4% | +97.8% | +10.5% | +2.3% |
| EBITDA | 243 | 186 | 154 | 114 | 96.02 | 54.48 | 50.93 |
| EBITDA margin | +14.9% | +15.0% | +14.3% | +12.3% | +12.0% | +13.3% | +13.6% |
| Profit before tax | 188 | 171 | 130 | 91.79 | 85.72 | 46.33 | 37.52 |
| Net profit | 140 | 128 | 94.32 | 66.28 | 63.96 | 34.37 | 27.87 |
| Net profit margin | +8.6% | +10.3% | +8.7% | +7.2% | +8.0% | +8.4% | +7.5% |
| EPS (₹) | 24.63 | 22.41 | 16.49 | 14.16 | 532.94 | 287.50 | 232.38 |
| Balance sheet | |||||||
| Total assets | 1,446 | 1,307 | 1,085 | 524 | 410 | 192 | 165 |
| Net worth | 1,091 | 959 | 831 | 323 | 209 | 145 | 110 |
| Total debt | 344 | 338 | 245 | 190 | 199 | 45.50 | 54.07 |
| Cash & bank | 3.87 | 68.17 | 86.75 | 18.88 | 2.44 | 11.89 | 5.18 |
| Net working capital | 515 | 436 | 349 | 266 | 216 | 94.45 | 92.77 |
| Cash flow | |||||||
| Cash from operations | 117 | 63.84 | 146 | 67.12 | 58.90 | 41.57 | 30.80 |
| Cash from investing | (107) | (152) | (499) | (90.84) | (188) | (19.67) | (6.04) |
| Cash from financing | (21.72) | 91.53 | 361 | 27.09 | 125 | (19.34) | (23.28) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 471 | 448 | 450 | 380 | 352 | 315 | 316 | 318 |
| Revenue growth (YoY) | +33.9% | +42.3% | +42.3% | +19.5% | +19.5% | +19.8% | +4.6% | +12.5% |
| Other income | 2.01 | 1.56 | 1.65 | 4.19 | 4.48 | 3.38 | 4.33 | 2.22 |
| EBITDA | 73.12 | 65.09 | 69.39 | 51.86 | 52.10 | 47.68 | 46.56 | 49.73 |
| EBITDA margin | +15.5% | +14.5% | +15.4% | +13.6% | +14.8% | +15.1% | +14.7% | +15.6% |
| Depreciation | 11.71 | 11.39 | 11.42 | 11.32 | 11.05 | 9.80 | 5.13 | 4.99 |
| Interest | 4.43 | 4.59 | 3.95 | 5.50 | 2.86 | 1.95 | 0.17 | 0.15 |
| Profit before tax | 58.99 | 50.67 | 55.67 | 39.23 | 42.67 | 39.31 | 45.59 | 46.81 |
| Tax | 14.86 | 12.59 | 13.53 | 9.57 | 11.67 | 9.74 | 11.39 | 11.81 |
| Net profit | 44.13 | 38.08 | 42.14 | 29.66 | 31.00 | 29.57 | 34.20 | 35.00 |
| EPS (₹) | 7.71 | 6.65 | 7.37 | 5.18 | 5.42 | 5.17 | 5.97 | 6.12 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,299 | 958 | 865 | 859 | 785 | 411 | 373 |
| Revenue growth | +37.3% | +10.4% | -0.4% | +10.7% | +92.9% | +10.5% | +9997.0% |
| EBITDA | 151 | 122 | 108 | 98.52 | 98.51 | 54.48 | 50.93 |
| EBITDA margin | +11.7% | +12.8% | +12.5% | +11.5% | +12.5% | +13.3% | +13.6% |
| Profit before tax | 112 | 120 | 93.70 | 78.29 | 88.64 | 46.33 | 37.52 |
| Net profit | 83.67 | 89.52 | 69.55 | 55.88 | 66.19 | 34.37 | 27.87 |
| Net profit margin | +6.4% | +9.3% | +8.0% | +6.5% | +8.4% | +8.4% | +7.5% |
| EPS (₹) | 14.63 | 15.63 | 11.91 | 11.99 | 55.15 | 287.50 | 232.38 |
| Balance sheet | |||||||
| Total assets | 1,215 | 1,146 | 970 | 516 | 390 | 192 | 165 |
| Net worth | 887 | 813 | 724 | 315 | 211 | 145 | 110 |
| Total debt | 321 | 329 | 244 | 190 | 176 | 45.03 | 54.07 |
| Cash & bank | 1.99 | 67.89 | 86.35 | 14.99 | 2.19 | 11.89 | 5.18 |
| Net working capital | 400 | 323 | 258 | 220 | 160 | 94.34 | 92.77 |
| Cash flow | |||||||
| Cash from operations | 34.11 | 19.80 | 112 | 39.28 | 58.34 | 41.57 | 30.80 |
| Cash from investing | (14.06) | (99.75) | (472) | (87.53) | (188) | (19.67) | (6.04) |
| Cash from financing | (33.99) | 83.86 | 368 | 51.29 | 125 | (19.33) | (23.28) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 400 | 358 | 364 | 290 | 287 | 243 | 249 | 240 |
| Revenue growth (YoY) | +39.6% | +47.7% | +46.4% | +20.7% | +26.5% | +22.4% | +5.1% | +13.4% |
| Other income | 2.70 | 2.68 | 3.21 | 4.63 | 4.32 | 4.36 | 3.49 | 4.28 |
| Total expenses | 346 | 320 | 317 | 261 | 252 | 214 | 216 | 207 |
| EBITDA | 54.05 | 38.64 | 47.00 | 29.32 | 34.82 | 28.18 | 32.50 | 33.18 |
| EBITDA margin | +13.5% | +10.8% | +12.9% | +10.1% | +12.1% | +11.6% | +13.1% | +13.8% |
| Depreciation | 9.68 | 9.40 | 9.41 | 9.48 | 9.08 | 7.81 | 3.08 | 3.07 |
| Interest | 4.03 | 3.98 | 3.47 | 5.21 | 2.77 | 1.87 | 0.13 | 0.08 |
| Profit before tax | 43.04 | 27.94 | 37.33 | 19.26 | 27.29 | 22.86 | 32.78 | 34.31 |
| Tax | 10.97 | 6.78 | 9.43 | 4.93 | 7.00 | 5.73 | 8.37 | 8.71 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 471 | 448 | 450 | 380 | 352 | 315 | 316 | 318 |
| Revenue growth (YoY) | +33.9% | +42.3% | +42.3% | +19.5% | +19.5% | +19.8% | +4.6% | +12.5% |
| Other income | 2.01 | 1.56 | 1.65 | 4.19 | 4.48 | 3.38 | 4.33 | 2.22 |
| EBITDA | 73.12 | 65.09 | 69.39 | 51.86 | 52.10 | 47.68 | 46.56 | 49.73 |
| EBITDA margin | +15.5% | +14.5% | +15.4% | +13.6% | +14.8% | +15.1% | +14.7% | +15.6% |
| Depreciation | 11.71 | 11.39 | 11.42 | 11.32 | 11.05 | 9.80 | 5.13 | 4.99 |
| Interest | 4.43 | 4.59 | 3.95 | 5.50 | 2.86 | 1.95 | 0.17 | 0.15 |
| Profit before tax | 58.99 | 50.67 | 55.67 | 39.23 | 42.67 | 39.31 | 45.59 | 46.81 |
| Tax | 14.86 | 12.59 | 13.53 | 9.57 | 11.67 | 9.74 | 11.39 | 11.81 |
| Net profit | 44.13 | 38.08 | 42.14 | 29.66 | 31.00 | 29.57 | 34.20 | 35.00 |
| EPS (₹) | 7.71 | 6.65 | 7.37 | 5.18 | 5.42 | 5.17 | 5.97 | 6.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,630 | 1,244 | 1,081 | 926 | 801 | 411 | 373 |
| Revenue growth | +31.2% | +14.1% | +14.0% | +15.4% | +97.8% | +10.5% | +2.3% |
| Other income | 7.42 | 12.05 | 12.49 | 9.20 | 2.88 | 1.37 | 1.30 |
| Total expenses | 1,387 | 1,058 | 927 | 813 | 705 | 356 | 322 |
| Employee cost | 167 | 117 | 90.66 | 54.80 | 40.46 | 22.33 | 20.24 |
| EBITDA | 243 | 186 | 154 | 114 | 96.02 | 54.48 | 50.93 |
| EBITDA margin | +14.9% | +15.0% | +14.3% | +12.3% | +12.0% | +13.3% | +13.6% |
| Depreciation | 45.18 | 24.78 | 15.96 | 11.08 | 7.50 | 5.59 | 10.08 |
| Interest | 16.90 | 2.41 | 21.46 | 19.97 | 5.68 | 3.93 | 4.63 |
| Profit before tax | 188 | 171 | 130 | 91.79 | 85.72 | 46.33 | 37.52 |
| Tax | 47.35 | 42.76 | 35.18 | 23.84 | 21.77 | 11.85 | 9.65 |
| Net profit | 140 | 128 | 94.32 | 66.28 | 63.96 | 34.37 | 27.87 |
| Net profit margin | +8.6% | +10.3% | +8.7% | +7.2% | +8.0% | +8.4% | +7.5% |
| EPS (₹) | 24.63 | 22.41 | 16.49 | 14.16 | 532.94 | 287.50 | 232.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 57.23 | 57.23 | 57.23 | 94.85 | 12.00 | 12.00 | 12.00 |
| Reserves & surplus | 1,034 | 902 | 774 | 229 | 197 | 133 | 98.35 |
| Shareholders' funds (net worth) | 1,091 | 959 | 831 | 323 | 209 | 145 | 110 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 342 | 335 | 241 | 163 | 149 | 37.94 | 42.76 |
| Unsecured loans | 1.96 | 2.94 | 4.05 | 27.26 | 50.05 | 7.56 | 11.31 |
| Total debt | 344 | 338 | 245 | 190 | 199 | 45.50 | 54.07 |
| Total liabilities | 1,446 | 1,307 | 1,085 | 524 | 410 | 192 | 165 |
| Assets | |||||||
| Gross block | 956 | 901 | 406 | 216 | 205 | 107 | 94.26 |
| Net block | 842 | 830 | 358 | 183 | 183 | 79.14 | 73.16 |
| Capital work in progress | 15.50 | 22.52 | 341 | 21.54 | 0.03 | 7.26 | 0.00 |
| Investments | 41.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 283 | 208 | 144 | 117 | 128 | 91.45 | 65.49 |
| Sundry debtors | 437 | 332 | 288 | 265 | 213 | 139 | 86.77 |
| Cash & bank balances | 3.87 | 68.17 | 86.75 | 18.88 | 2.44 | 11.89 | 5.18 |
| Loans & advances | 157 | 87.88 | 60.50 | 41.06 | 35.54 | 28.57 | 13.63 |
| Total current assets | 882 | 696 | 580 | 442 | 379 | 270 | 171 |
| Total current liabilities | 367 | 260 | 231 | 176 | 163 | 176 | 78.30 |
| Net working capital | 515 | 436 | 349 | 266 | 216 | 94.45 | 92.77 |
| Total assets | 1,446 | 1,307 | 1,085 | 524 | 410 | 192 | 165 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 15.52 | 11.73 | 3.53 | 0.15 | 4.80 | 2.24 | 0.75 |
| Net cash from operating activities | 117 | 63.84 | 146 | 67.12 | 58.90 | 41.57 | 30.80 |
| Net cash from investing activities | (107) | (152) | (499) | (90.84) | (188) | (19.67) | (6.04) |
| Net cash from financing activities | (21.72) | 91.53 | 361 | 27.09 | 125 | (19.34) | (23.28) |
| Net change in cash | (12.32) | 3.79 | 8.20 | 3.37 | (4.64) | 2.56 | 1.48 |
| Closing cash | 3.87 | 68.17 | 86.75 | 18.88 | 2.44 | 11.89 | 5.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +31.1% | +15.0% | +16.7% | +15.7% | +94.9% | +10.0% | +4.9% |
| EBITDA growth | +30.5% | +20.5% | +35.9% | +18.4% | +76.3% | +7.0% | +24.9% |
| PBT growth | +10.1% | +32.0% | +41.1% | +7.1% | +85.0% | +23.5% | +51.6% |
| Net income growth | +9.3% | +36.1% | +42.3% | +3.6% | +86.1% | +23.3% | +40.3% |
| Revenue CAGR (3Y) | +20.7% | +15.8% | +38.1% | +35.4% | +31.0% | - | - |
| EBITDA CAGR (3Y) | +28.8% | +24.7% | +41.5% | +30.7% | +33.0% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +8.6% | +10.3% | +8.7% | +7.3% | +8.0% | +8.4% | +7.5% |
| Return on capital employed | +14.9% | +14.5% | +18.8% | +23.9% | +30.4% | +28.2% | +26.3% |
| Return on net worth | +13.8% | +14.3% | +17.0% | +28.0% | +36.2% | +27.0% | +28.9% |
| Debt / equity | 0.33 | 0.33 | 0.38 | 0.73 | 0.69 | 0.39 | 0.65 |
| Long-term debt / equity | 0.22 | 0.25 | 0.26 | 0.29 | 0.21 | 0.07 | 0.20 |
| Interest cover | 8.55 | 1.49 | 15.50 | 19.47 | 6.42 | 8.04 | 11.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.76 | 1.90 | 3.47 | 4.39 | 5.13 | 4.09 | 4.06 |
| Inventory turnover | 6.64 | 7.07 | 8.28 | 7.54 | 7.28 | 5.23 | 7.16 |
| Debtors turnover | 4.24 | 4.01 | 3.91 | 3.88 | 4.56 | 3.65 | 4.20 |
| EPS (₹) | 24.63 | 22.41 | 16.49 | 14.16 | 532.94 | 287.50 | 232.38 |
| Dividend per share (₹) | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 190.61 | 167.66 | 145.20 | 57.61 | 1,738.38 | 1,206.84 | 919.62 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 400 | 358 | 364 | 290 | 287 | 243 | 249 | 240 |
| Revenue growth (YoY) | +39.6% | +47.7% | +46.4% | +20.7% | +26.5% | +22.4% | +5.1% | +13.4% |
| Other income | 2.70 | 2.68 | 3.21 | 4.63 | 4.32 | 4.36 | 3.49 | 4.28 |
| Total expenses | 346 | 320 | 317 | 261 | 252 | 214 | 216 | 207 |
| EBITDA | 54.05 | 38.64 | 47.00 | 29.32 | 34.82 | 28.18 | 32.50 | 33.18 |
| EBITDA margin | +13.5% | +10.8% | +12.9% | +10.1% | +12.1% | +11.6% | +13.1% | +13.8% |
| Depreciation | 9.68 | 9.40 | 9.41 | 9.48 | 9.08 | 7.81 | 3.08 | 3.07 |
| Interest | 4.03 | 3.98 | 3.47 | 5.21 | 2.77 | 1.87 | 0.13 | 0.08 |
| Profit before tax | 43.04 | 27.94 | 37.33 | 19.26 | 27.29 | 22.86 | 32.78 | 34.31 |
| Tax | 10.97 | 6.78 | 9.43 | 4.93 | 7.00 | 5.73 | 8.37 | 8.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,299 | 958 | 865 | 859 | 785 | 411 | 373 |
| Revenue growth | +37.3% | +10.4% | -0.4% | +10.7% | +92.9% | +10.5% | +9997.0% |
| Other income | 13.24 | 16.78 | 10.72 | 8.73 | 2.86 | 1.37 | 1.30 |
| Total expenses | 1,147 | 836 | 757 | 760 | 687 | 356 | 322 |
| Employee cost | 111 | 62.74 | 50.11 | 43.60 | 36.30 | 22.22 | 20.24 |
| EBITDA | 151 | 122 | 108 | 98.52 | 98.51 | 54.48 | 50.93 |
| EBITDA margin | +11.7% | +12.8% | +12.5% | +11.5% | +12.5% | +13.3% | +13.6% |
| Depreciation | 37.37 | 17.02 | 11.40 | 10.66 | 7.40 | 5.59 | 10.08 |
| Interest | 15.42 | 2.17 | 13.59 | 18.30 | 5.33 | 3.93 | 4.63 |
| Profit before tax | 112 | 120 | 93.70 | 78.29 | 88.64 | 46.33 | 37.52 |
| Tax | 28.14 | 30.42 | 25.53 | 20.75 | 22.46 | 11.85 | 9.65 |
| Net profit | 83.67 | 89.52 | 69.55 | 55.88 | 66.19 | 34.37 | 27.87 |
| Net profit margin | +6.4% | +9.3% | +8.0% | +6.5% | +8.4% | +8.4% | +7.5% |
| EPS (₹) | 14.63 | 15.63 | 11.91 | 11.99 | 55.15 | 287.50 | 232.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 57.23 | 57.23 | 57.23 | 94.85 | 12.00 | 12.00 | 12.00 |
| Reserves & surplus | 829 | 756 | 666 | 220 | 199 | 133 | 98.35 |
| Shareholders' funds (net worth) | 887 | 813 | 724 | 315 | 211 | 145 | 110 |
| Secured loans | 319 | 326 | 240 | 163 | 139 | 37.94 | 42.76 |
| Unsecured loans | 1.95 | 2.91 | 3.86 | 27.07 | 36.99 | 7.09 | 11.31 |
| Total debt | 321 | 329 | 244 | 190 | 176 | 45.03 | 54.07 |
| Total liabilities | 1,215 | 1,146 | 970 | 516 | 390 | 192 | 165 |
| Assets | |||||||
| Gross block | 745 | 698 | 208 | 195 | 185 | 94.93 | 83.23 |
| Net block | 648 | 637 | 164 | 161 | 161 | 79.14 | 73.15 |
| Capital work in progress | 15.27 | 21.02 | 339 | 21.54 | 0.03 | 7.26 | 0.00 |
| Investments | 101 | 60.00 | 60.00 | 60.00 | 60.00 | 0.00 | 0.00 |
| Inventories | 204 | 140 | 93.99 | 97.27 | 105 | 91.45 | 65.49 |
| Sundry debtors | 330 | 249 | 217 | 230 | 174 | 139 | 86.77 |
| Cash & bank balances | 1.99 | 67.89 | 86.35 | 14.99 | 2.19 | 11.89 | 5.18 |
| Loans & advances | 172 | 72.37 | 39.70 | 36.45 | 31.95 | 28.57 | 13.63 |
| Total current assets | 709 | 529 | 437 | 378 | 313 | 270 | 171 |
| Total current liabilities | 309 | 206 | 180 | 158 | 153 | 176 | 78.30 |
| Net working capital | 400 | 323 | 258 | 220 | 160 | 94.34 | 92.77 |
| Total assets | 1,215 | 1,146 | 970 | 516 | 390 | 192 | 165 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 15.31 | 11.39 | 3.14 | 0.10 | 4.80 | 2.23 | 0.75 |
| Net cash from operating activities | 34.11 | 19.80 | 112 | 39.28 | 58.34 | 41.57 | 30.80 |
| Net cash from investing activities | (14.06) | (99.75) | (472) | (87.53) | (188) | (19.67) | (6.04) |
| Net cash from financing activities | (33.99) | 83.86 | 368 | 51.29 | 125 | (19.33) | (23.28) |
| Net change in cash | (13.94) | 3.92 | 8.25 | 3.03 | (4.69) | 2.56 | 1.48 |
| Closing cash | 1.99 | 67.89 | 86.35 | 14.99 | 2.19 | 11.89 | 5.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +35.6% | +10.8% | +0.7% | +9.3% | +91.3% | +10.0% | +9997.0% |
| EBITDA growth | +23.8% | +13.3% | +9.6% | +0.0% | +80.8% | +7.0% | +9997.0% |
| PBT growth | -6.7% | +27.9% | +19.7% | -11.7% | +91.3% | +23.5% | +9997.0% |
| Net income growth | -6.5% | +28.7% | +24.5% | -15.6% | +92.6% | +23.3% | +9997.0% |
| Revenue CAGR (3Y) | +14.8% | +6.9% | +28.2% | +32.0% | - | - | - |
| EBITDA CAGR (3Y) | +15.4% | +7.5% | +25.6% | +24.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +6.4% | +9.3% | +7.9% | +6.7% | +8.4% | +8.4% | +7.5% |
| Return on capital employed | +10.8% | +11.5% | +14.4% | +21.3% | +32.3% | +28.2% | +25.5% |
| Return on net worth | +9.9% | +11.6% | +13.7% | +24.0% | +37.2% | +27.0% | +25.3% |
| Debt / equity | 0.38 | 0.37 | 0.42 | 0.70 | 0.62 | 0.39 | 0.49 |
| Long-term debt / equity | 0.27 | 0.30 | 0.29 | 0.30 | 0.21 | 0.07 | 0.11 |
| Interest cover | 13.53 | 2.06 | 14.07 | 20.83 | 5.85 | 8.04 | 11.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.80 | 2.11 | 4.29 | 4.52 | 5.61 | 4.61 | 4.49 |
| Inventory turnover | 7.55 | 8.19 | 9.04 | 8.48 | 7.98 | 5.23 | 5.70 |
| Debtors turnover | 4.49 | 4.11 | 3.87 | 4.26 | 5.03 | 3.65 | 4.30 |
| EPS (₹) | 14.63 | 15.63 | 11.91 | 11.99 | 55.15 | 287.50 | 232.38 |
| Dividend per share (₹) | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 154.94 | 142.06 | 126.47 | 55.90 | 175.69 | 1,206.84 | 919.62 |
Shareholding Pattern of Innova Captab Limited
Shareholding for the quarter ended Sep 2026: promoters hold 50.90%, foreign institutional investors hold 0.30%, domestic institutional investors hold 20.00% and retail and other public shareholders hold 28.80%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 50.90% | 50.90% | 50.90% | 50.90% |
| Public | 49.10% | 49.10% | 49.10% | 49.10% |
Group Structure of Innova Captab Limited
Innova Captab has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Sharon Bio Medicine Limited | U24110MH1989PLC052251 | - |
| Univentis Medicare Limited | U24232MH2015PLC402722 | - |
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Innova Captab
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jul 2025 | Hdfc Bank Limited | ₹52.32 Cr | Open |
| 29 Sep 2022 | Hdfc Bank Limited | ₹150 Cr | Open |
| 29 Sep 2022 | Hdfc Bank Limited | ₹20 Cr | Open |
| 31 Aug 2017 | Yes Bank Limited | ₹48 Cr | Open |
| 01 Nov 2011 | State Bank of India | ₹235 Cr | Open |
Total charge records: 17 View all charges
Employees and EPFO Compliance at Innova Captab
Innova Captab Limited has a workforce of 1,246 employees as of Jan 09, 2026.
Employee and EPFO history for Innova Captab Limited
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Innova Captab
Innova Captab has 8 GST registrations: 6 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCH5082R1ZZ | Maharashtra | Active | 25 Oct 2023 |
| 02AABCH5082R2ZA | Himachal Pradesh | Active | 01 Jul 2017 |
| 01AABCH5082R1ZD | Jammu and Kashmir | Active | 24 Mar 2022 |
| 06AABCH5082R1Z3 | Haryana | Active | 01 Jul 2022 |
GST registrations and filing compliance for Innova Captab Limited
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Innova Captab
Credit ratings, litigation, and regulatory alerts for Innova Captab Limited
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Innova Captab
MSME payment history for Innova Captab Limited
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Innova Captab
Corporate group structure for Innova Captab Limited
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Innova Captab
MCA filings and documents for Innova Captab Limited
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Innova Captab
Recent News on Innova Captab
Frequently Asked Questions about Innova Captab Limited
Innova Captab is an active public limited company based in Thane, Maharashtra, India. The company works in chemical products, within the chemicals industry. It was incorporated on 03 January 2005 (21+ years old) and is registered under CIN L24246MH2005PLC150371.
Innova Captab reported revenue of ₹1,630.02 Cr for FY 2025-26 (up 31.06% YoY) based on consolidated financials.
Innova Captab has 8 current directors:
- Vinay Kumar Lohariwala - Managing Director
- Jayant Vasudeo Rao - Whole-Time Director
- Manoj Kumar Lohariwala - Whole-Time Director
- Shirish Gundopant Belapure - Director
- Sudhir Kumar Bassi - Director
- Priyanka Dixit - Director
- Archit Aggarwal - Director
- Mahendar Korthiwada - Director
The GSTIN of Innova Captab is 27AABCH5082R1ZZ, registered in Maharashtra. The company has 8 GST registrations in all, of which 6 are active and 2 are cancelled or inactive. Other active GSTINs include 02AABCH5082R2ZA (Himachal Pradesh), 01AABCH5082R1ZD (Jammu and Kashmir), 06AABCH5082R1Z3 (Haryana).
The CIN (Corporate Identification Number) of Innova Captab is L24246MH2005PLC150371. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes, Innova Captab is a listed company.
Innova Captab was incorporated on 03 January 2005, making it 21+ years old. It is registered with the Registrar of Companies, Mumbai.
Innova Captab can be reached through the website innovacaptab.com. Its registered office is in Thane, Maharashtra, India.
The registered office of Innova Captab is at 1513 15th Floor Satra Plaza Chs Ltd., Plot No. 19 & 20 Sector – 19D Vashi Navi Mumbai, Thane, Maharashtra, India – 400703.